CytomX Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 09/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | — |
| Research and development | $68.7M | $83.4M | $77.7M | $111.6M | — |
| Operating expenses | $98.6M | $113.1M | $107.7M | $154.5M | — |
| Operating income | -$22.4M | $25.0M | -$6.5M | -$101.3M | — |
| Pretax income | -$17.1M | $32.1M | $3.3M | -$99.3M | — |
| Income tax expense | $238,000 | $224,000 | $3.9M | $0 | — |
| Net income | -$17.4M | $31.9M | -$569,000 | -$99.3M | — |
| Balance Sheet | |||||
| Cash and equivalents | $12.7M | $38.1M | $17.2M | $193.7M | — |
| Current assets | $143.9M | $107.3M | $182.9M | $237.1M | — |
| Total assets | $151.6M | $120.5M | $201.8M | $260.9M | — |
| Current liabilities | $46.6M | $85.8M | $155.9M | $152.6M | $123.6M |
| Total liabilities | $52.6M | $121.0M | $249.2M | $346.6M | $307.0M |
| Stockholders' equity | $99.0M | -$456,000 | -$47.4M | -$85.8M | -$80.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$75.6M | -$86.2M | -$56.0M | -$110.8M | — |
| Depreciation and amortization | $1.2M | $1.6M | $2.0M | $2.3M | — |
| Stock-based compensation | $6.3M | $7.7M | $8.6M | $13.1M | — |
| Capital expenditure | $220,000 | $310,000 | $840,000 | $1.7M | — |
| Free cash flow | -$75.8M | -$86.5M | -$56.9M | -$112.5M | — |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 217.7M · Free float 99.0%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.